1. Vallakati A., Sharma A., Madmani M. et al. Efficacy and Safety of Novel Oral Anticoagulants for Atrial Fibrillation Ablation: An Updated Meta-Analysis. // Cardiol Ther 2016; 5(1): 85-100.
2. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation // Europace 2015; 17(10): 1467-507.
3. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO) // Eur Heart J 2016. pii: ehw210. [в печати].
4. Calkins H., Kuck K.H., Cappato R. et al. 2012 HRS/ EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design // Europace 2012; 14(4): 528-606.
5. Клинические рекомендации ВНОА по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиарит-мических устройств. Доступно на: http://www.vnoa.ru/literature/Recomend2013.pdf.
6. Михайлов Е.Н., Лебедев Д.С., Гуреев С.В. и др. Безопасность одновременного применения непрямых и прямых антикоагулянтов при катерной аблации фибрилляции предсердий: исследование на большой группе пациентов // Вестник аритмологии. - 2008. - №. 53. -С. 21-26.
7. Wazni O.M., Beheiry S., Fahmy T., et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period // Circulation 2007; 116(22): 2531-4.
8. Mikhaylov E.N., Orshanskaya V.S., Lebedev A.D. et al. Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study // J Cardiovasc Electrophysiol 2013; 24(8): 888-93.
9. Cappato R., Marchlinski F.E., Hohnloser S.H., et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation // Eur Heart J 2015; 36(28): 1805-11.
10. Providência R., Marijon E., Albenque J.P., et al. Rivaroxaban and Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation // Europace 2014; 16(8): 1137-1144.
11. Казаков А.И., Яшин С.М., Лян Е.В., Айрапетян А.В. Новые пероральные антикоагулянты при катетер-ной абляции фибрилляции предсердий. Опыт применения ривароксабана // Кардиология 2015; 8: 30-34.
12. Mikhaylov E.N., Lebedev D.S., Pokushalov E.A. et al. Outcomes of Cryoballoon Ablation in High- and Low-Vol-ume Atrial Fibrillation Ablation Centres: A Russian Pilot Survey // Biomed Res Int 2015; 2015: 591603.
13. Saksena S., Sra J., Jordaens L., et al. A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography in patients with atrial fibrillation: the intracardiac echocardiography guided cardioversion helps interventional procedures study // Circ Arrhythm Electrophysiol 2010; 3(6): 571-7.
14. Dunn A.S., Turpie A.G. Perioperative management of patients receiving oral anticoagulants: a systematic review // Arch Intern Med 2003; 163(8): 901-8.
15. Garcia D.A., Regan S., Henault L.E., et al. Risk of thromboembolism with short-term interruption of warfarin therapy // Arch Intern Med 2008; 168(1): 63-9.
16. Korantzopoulos P., Letsas K.P., Liu T., et al. Anticoagulation and antiplatelet therapy in implantation of electrophysiological devices. Europace 2011; 13(12): 1669-80.
Послать статью по эл. почте 